Compare ConocoPhillips (COP) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Revvity Inc — how do they compare? ConocoPhillips trades at $134.1 (market cap $161.21B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: ConocoPhillips is far larger — about 9.5× Revvity Inc's market cap, and ConocoPhillips pays the higher dividend (2.5%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Revvity Inc for 12 Days on average.
| COP | RVTY | |
|---|---|---|
Market Cap | $161.21B | $16.98B |
Volume | 6,058,403 | 1,456,900 |
Sector | Energy | Health |
52-Week High | $141.22 | $157.36 |
52-Week Low | $85.66 | $82.26 |
Typical Hold Time | 79 Days | 12 Days |
Enterprise Value | $176.81B | $19.30B |
Dividend Yield | 2.5% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.19, up 3.35% with strong technical momentum. The stock shows robust fundamentals with a P/E of 17.75, net income margin of 14.65%, and consistent earnings beats in recent quarters. Recent developments include a 20-year LNG supply agreement with Venture Global and potential asset sales in Norway and the UK. Technical indicators show bullish moving averages with the stock trading near pivot point resistance at $134.
COP presents a compelling investment case with strong analyst support (75% buy rating) and a $154.75 price target offering 15% upside. However, investors face risks from oil price volatility, geopolitical tensions affecting international operations, and declining profit margins from 23.79% in 2022 to 13.55% in 2025. The company's solid cash flow generation and strategic LNG expansion provide growth catalysts.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
